Healthcare Is Beating Chips

Start with a single number: since semiconductors peaked on June 22, the iShares Biotechnology ETF (IBB) has climbed more than 20% and the Health Care Select Sector SPDR Fund (XLV) has gained roughly 16%. The iShares Semiconductor ETF (SOXX) has fallen just under 20% over the same period. That is a 36-point swing between two sectors institutional investors treated, for the better part of three years, as if they occupied different planets.

They do not. Capital is finite, and right now it is moving from one to the other with unusual conviction.

An Unloved Sector Turns

What makes this more than a short-term relief trade is where the money was sitting before it arrived in healthcare ETFs. According to Todd Sohn, chief ETF strategist at Baird Strategas, healthcare ETFs suffered more than $20 billion in combined outflows from 2023 through 2025. So far in 2026, the sector has pulled in about $4.5 billion. Even after weeks of outperformance, healthcare’s returns versus the S&P 500 over the past three years still rank among the weakest 10% of periods in Sohn’s historical data.

The institutional exodus was deep enough that the rebound, even after a sustained run, has barely closed the valuation gap the outflows created. Healthcare and biotech are reaching new highs after years of underperformance, while ETF investors are only beginning to return. That asymmetry is the core of the opportunity argument.

Semiconductor stocks now make up roughly 42% of the S&P 500 tech sector and about 20% of the full index. Passive investors, whether they know it or not, are running a concentrated bet on AI-adjacent chip names. When that concentration unwinds, even partially, it generates outsized flows into sectors that never got crowded. Healthcare was never crowded.

Why the Chip Bounce Keeps Failing

The healthcare rally was already well underway before SOXX rolled over again after its latest rebound fizzled. Chip sellers regained control, stepping in after SOXX had recovered roughly half of its June-to-July drop. That failure at the halfway mark matters. When a cyclical recovery attempt stalls there, it tends to accelerate capital toward whatever is already working. Healthcare was already working.

The broader framing, consistent with market commentary from Prospero.ai’s July trading letters, is that capital is shifting out of high-beta semiconductors and growth names into defensive value, healthcare, and under-owned small caps, rather than pushing benchmark indices back toward record highs. This is not a bet on macro recovery. It is a bet on a leadership change while the broad index digests the AI trade’s first serious correction.

The Earnings Engine

The fundamentals driving this rotation are real, and Eli Lilly is where they are most visible. Lilly reported Q2 2026 earnings and revenue that easily beat estimates, then raised its full-year sales outlook to between $85 billion and $87 billion, up from prior guidance of $82 billion to $85 billion. Mounjaro’s worldwide revenue rose 91% to $9.94 billion for the quarter, including $4.8 billion in U.S. sales alone.

Lilly posted Q2 non-GAAP EPS of $8.38. For context: that is the largest company in the S&P 500 healthcare sector posting a result that reset the earnings base for every analyst model tracking the stock. Q2 also marked the first report to include sales of Foundayo, Lilly’s newly launched oral GLP-1 pill for obesity, which won FDA approval in April.

The structural catalyst beneath Lilly’s numbers is the Medicare GLP-1 Bridge, a CMS demonstration program that launched July 1, 2026, and runs through December 31, 2027. Eligible Medicare Part D beneficiaries can now access Zepbound and Wegovy for a $50 monthly copayment, outside of standard Part D coverage. A prior KFF analysis estimated close to 14 million Medicare beneficiaries had a diagnosis of overweight or obesity in 2020, though eligibility criteria under the Bridge reduce that number in practice.

Volume is the mechanism here, not price. Lilly CEO David Ricks has estimated that global GLP-1 use will rise from approximately 20 million patients at the end of 2025 to 30 million by the end of 2026. Coverage expansion writes those prescriptions. Earnings follow prescriptions.

The M&A Floor Nobody Is Pricing

Beyond earnings, healthcare has a second engine running that semiconductors currently lack: a sustained buy-side bid from large pharma balance sheets racing against patent cliffs. According to PwC’s midyear outlook for pharmaceutical and life sciences deals, deal value surpassed $65 billion in the first quarter of 2026 alone, the strongest single quarter since 2020, with 16 biopharma transactions valued at $1 billion or more. Q2 added another $55.1 billion across 48 deals, bringing H1 2026 biopharma M&A to $96 billion across 80 transactions, according to J.P. Morgan’s deal tracker.

The strategic logic is straightforward. PwC estimates that more than $300 billion in branded pharmaceutical revenue faces loss-of-exclusivity pressure this decade. Large pharma has little choice but to acquire. Sun Pharma’s $11.75 billion acquisition of Organon and GSK’s $10.6 billion purchase of Nuvalent are the two largest healthcare transactions of the year so far. Merck closed its $6.7 billion acquisition of Terns Pharmaceuticals in May, expanding its oncology pipeline. Lilly proposed a $6.3 billion acquisition of Centessa in March.

Medtech is also running. Medtech deal value reached $36.5 billion in the first half of 2026, according to PwC, following a decade-high year in 2025. PwC expects the second half of 2026 to see continued bolt-on activity in oncology, metabolic disease, vaccines, and radiopharmaceuticals.

A sector with this level of M&A activity has a natural price floor. Acquirers are telling the market, in cash, what target valuations are worth to them. That bid is still largely unpriced in small and mid-cap biotech.

Bull Case

Three legs, each independently valid. First: earnings acceleration driven by GLP-1 volume expansion and Medicare coverage opening a new patient pathway for eligible beneficiaries through the Bridge. Second: M&A support, with large pharma writing acquisition checks at premiums that put a floor under biotech valuations across the size spectrum. Third: flows that are still early-stage. Healthcare ETFs have taken in roughly $4.5 billion in 2026 against more than $20 billion in recent-year outflows. The money coming back is a fraction of what left. For a sector that spent years unloved, an early return of institutional interest could give the breakout considerably more room to run than it has already used.

Bear Case

The risks deserve honest treatment. XLV’s heavy weighting in Eli Lilly means any clinical disappointment, meaningful competitive pricing pressure from Novo Nordisk, or revision to Medicare reimbursement terms hits the whole sector’s headline number in a single session. Concentration in a single name is a structural vulnerability, not just a theoretical one.

Managed care is a separate problem. Insurers face regulatory headwinds and rising medical loss ratios, making insurance-specific exposure more volatile than the broad sector. A managed care earnings miss heading into Q3 would test the thesis quickly. And if SOXX stabilizes and reclaims its prior high, the rotation trade loses its relative strength argument. The chip recovery failing twice is meaningful. A third attempt that holds would change the picture.

What to Watch

Three metrics will tell whether this breakout is structural or a two-month relief trade. First, weekly ETF flows into XLV and IBB. Sohn at Baird Strategas has flagged that healthcare flows are accelerating after dismal demand over the last three years, but $4.5 billion barely offsets a fraction of the more than $20 billion that left. If flows stall, the momentum argument cracks. Second, GLP-1 prescription volume data for Q3, with Lilly’s next earnings report the scheduled checkpoint. Third, SOXX. If chip sellers absorb another bounce and the ETF retests its lows, healthcare gets another leg of relative inflow. If SOXX reverses hard and holds, institutional money faces a genuine choice about where to deploy.

Bottom Line

The chip bear market did not just punish semiconductor investors. It created the conditions for one of the cleanest sector rotations in years. Healthcare arrived at this moment cheap on a relative basis, unloved by flows, improving on fundamentals, and now receiving a genuine policy tailwind through Medicare GLP-1 Bridge access. That combination rarely assembles itself this clearly.

The question is not whether the breakout is real. It is whether investors who spent three years avoiding this sector will show up early enough to matter, or late enough to pay for someone else’s conviction.